Between March and July, 2003, a global outbreak of severe acute respiratory syndrome (SARS) caused more than 8000 probable or confirmed cases and 774 deaths in 25 countries across five continents.[@bib1] During this outbreak, international cooperation enabled the rapid identification of the SARS-coronavirus (SARS-CoV) and dissemination of information through fast-track publication. However, even after 8000 cases a common therapeutic approach has not been established, and in-vivo evidence remains inconclusive for almost all drugs investigated.[@bib2] In June, 2012, Zaki and colleagues[@bib3] reported for the first time a case of infection with Middle East respiratory syndrome coronavirus (MERS-CoV) in a 60-year-old man, with rapid, progressive pneumonia leading to acute respiratory distress syndrome. Other documented cases,[@bib4], [@bib5], [@bib6] and our own findings,[@bib7] show a continuous evolution from pneumonia to respiratory failure and acute respiratory distress syndrome.

In *The Lancet Infectious Diseases*, Drosten and colleagues[@bib8] report the case of a 73-year-old man admitted for respiratory distress. He rapidly developed renal failure and died 10 days after admission as a result of septic shock and multiple organ failure. This study provides a quantitative analysis of viral shedding over time and adds to our knowledge of the natural history of this new virus. The data show the value of samples from the lower respiratory tract compared with samples from the upper respiratory tract for diagnostics, as previously suggested.[@bib8] Viral load in the lower respiratory tract decreases over time, but whether this decrease is linked to the development of a specific antibody response is unknown. The investigators report consistent detection of MERS-CoV in stool on days 12 and 16, but at very low concentrations by contrast with faecal shedding of SARS-CoV.[@bib1] The potential value of stool samples taken early in the course of disease is unknown; stool samples should be collected for the investigation of MERS-CoV, especially when patients present with diarrhoea at onset.[@bib5], [@bib7] Of interest is the detection of low concentrations of MERS-CoV in urine at the time the patient developed renal failure, a feature reported in several patients with MERS.[@bib3], [@bib5], [@bib7] The researchers suggest that the kidneys might be primary targets for MERS-CoV, although high viral loads in urine would have been expected. An alternative hypothesis is that the presence of small amounts of virus in urine[@bib8] and blood[@bib7] could be a hallmark of systemic viral spread, and potentially a marker of disease severity and poor prognosis. The rapid progression of MERS towards septic shock, multiorgan failure, and death in this patient is consistent with this hypothesis.

Although based on few sequences, the phylogenetic analysis provided in the report by Drosten and colleagues dates the time of the common ancestor to mid-2011 (ie, about 1 year before the earliest confirmed cases in Jordan), which suggests that the virus could have spread unnoticed in that time. Furthermore, the analysis suggests geographical clustering of viruses in eastern (Qatar, United Arab Emirates) and western (Jordan, Saudi Arabia) parts of the Arabian Peninsula, which could reflect either repeated introductions or distinct, sustained lineages of human-to-human transmission.

On the basis of the timeline of SARS, the MERS outbreak could still be in the early phase. Now is the time to design and assess therapeutic protocols. Drosten and colleagues provide valuable data for the pathophysiology of MERS-CoV infection; the evolution shown for viral load could provide a timeframe for therapy. From the cases described in the scientific literature the observation of a worsening of respiratory status, from influenza-like symptoms to pneumonia and then acute respiratory distress syndrome, hints at a potential window for treatment. SARS treatment protocols could be used, but the major differences in host responses[@bib9] and susceptibility to drugs such as interferon-alfa[@bib10] for these two coronaviruses should be kept in mind.[@bib8] Interferon with or without ribavirin is a promising candidate treatment.[@bib10], [@bib11] Other options are under investigation, such as inhibition of the main protease,[@bib12] convalescent plasma,[@bib13] or monoclonal antibodies. The research community should learn from SARS and use these data to keep one step ahead of the outbreak. A single international therapeutic protocol, building on the generic [ISARIC/WHO protocol](http://www.prognosis.org/isaric/){#interrefs10} for severe acute respiratory infections, is needed to identify effective intervention strategies.
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